Sanofi Aventis CEO Chris Viehbacher Insists Genzyme Deal at a reasonable price
Posted on September 15, 2010 at 08:20 AM EDT
French drugmaker Sanofi Aventis SA (SASY), world’s fourth-biggest pharmaceutical company, Chief Executive Officer Chris Viehbacher sees a reasonable chance of buying Genzyme (GENZ) at a fair price, but expects it will take some time to agree a deal. Chris Viehbacher, seeking support for his $18.5 billion bid for Genzyme Corp., said he met with investors [...]